TrialJournal of hematology & oncology2023

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.

Nicholas J Short et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.